The business transformation (manufacturing sale + royalty monetization) removes near-term financing overhang and positions MGNX for pipeline catalysts in mid-2026. Traders should watch for MGC026 Phase 1 data in mid-2026, which could be a major inflection point. The stock may re-rate on reduced dilution risk and extended runway.
Price Chart
Executive Summary
MacroGenics reported Q1 2026 revenue of $20.8M (up 57% YoY) and net loss of $36.8M, essentially in line with EPS consensus of -$0.57 (actual -$0.58). More importantly, the company announced a manufacturing divestiture and ZYNYZ royalty monetization expected to provide up to $202.5M in non-dilutive capital, extending cash runway through 2028 and reducing near-term financing risk.
Key Financial Metrics
Key Facts
- Revenue grew 57% YoY to $20.8M driven by contract manufacturing and royalty revenue
- Net loss narrowed to $36.8M from $41.0M in Q1 2025
- EPS of -$0.58 vs consensus -$0.57 (in line)
- Manufacturing operations divestiture to Bora Pharmaceuticals for $122.5M upfront
- Expanded ZYNYZ royalty monetization with Sagard: $60M received plus up to $20M milestone
- Cash runway extended through 2028, up from late 2027 prior guidance
- ADC pipeline on track for multiple data readouts in mid-2026 (MGC026, MGC028, lorigerlimab)
- Lorigerlimab showed 25% objective response rate in CCGC; ovarian cancer program halted
Financial Impact
Manufacturing divestiture and royalty monetization provide up to $202.5M in non-dilutive capital, significantly reducing dilution risk and extending cash runway through 2028.
Risk Factors
- Manufacturing divestiture closing conditions (expected Q3 2026) - transaction risk
- Pipeline data readouts are binary events - clinical failure could erase value
- Partial clinical hold on lorigerlimab LINNET study remains unresolved
- Sagard milestone payment dependent on ZYNYZ 2026 sales performance
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001125345-26-000040 |
| Document: mgnx-20260513.htm | 0001125345-26-000040 |
| Document: 0001125345-26-000040-index-headers.html | 0001125345-26-000040 |
| Document: 0001125345-26-000040-index.html | 0001125345-26-000040 |
| Document: 0001125345-26-000040.txt | 0001125345-26-000040 |
| 8-K Data (Synthetic) | 0001125345-26-000040 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Jul 8, 2026 12w ago | 8-K | $4.57 $4.01 | ▼ −12.25% | ▼ −14.50% | $3.58 (−21.66%) |
Jul 2, 2026 13w ago | Press Release | $4.71 $3.78 | ▼ −19.75% | ▼ −19.33% | $3.58 (−23.99%) |
Jun 12, 2026 16w ago | Institutional Cluster | $3.96 $4.33 | ▲ +9.34% | ▲ +7.56% | $3.58 (−9.60%) |
Jun 11, 2026 16w ago | Institutional Cluster | $4.01 $4.57 | ▲ +13.97% | ▲ +12.07% | $3.58 (−10.72%) |
May 13, 2026 20w ago | 8-K | $4.16 $3.96 | ▼ −4.81% | ▼ −3.95% | $3.58 (−13.94%) |
May 12, 2026 20w ago | 8-K | $3.52 $3.87 | ▲ +9.94% | ▲ +11.67% | $3.58 (+1.70%) |
May 11, 2026 20w ago | Press Release | $3.52 $3.87 | ▲ +9.94% | ▲ +11.67% | $3.58 (+1.70%) |
Apr 8, 2026 25w ago | 8-K | $3.44 $3.01 | ▼ −12.50% | ▼ −20.07% | $3.58 (+4.07%) |
Apr 8, 2026 25w ago | Press Release | $3.44 $3.01 | ▼ −12.50% | ▼ −20.07% | $3.58 (+4.07%) |
Apr 8, 2026 25w ago | DEFA14A | $3.44 $3.01 | ▼ −12.50% | ▼ −20.07% | $3.58 (+4.07%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access